Is Jenburkt Pharma overvalued or undervalued?

As of 11 July 2025, Jenburkt Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 18.49, an EV to EBITDA of 14.12, and a PEG ratio of 0.80, which suggests that while the company has growth potential, its current price may not fully reflect its earnings growth prospects.
In comparison to its peers, Jenburkt Pharma's PE ratio is significantly lower than Sun Pharma's 35.09 and Divi's Lab's 82.88, both of which are categorized as very expensive. However, it is also higher than Dr. Reddy's Labs at 18.5 and Aurobindo Pharma at 18.9, which are considered attractive. Notably, Jenburkt Pharma has outperformed the Sensex over the past year, with a return of 50.84% compared to the Sensex's 3.26%, reinforcing the notion that while the stock has performed well, it may still be overvalued relative to its fundamentals.